• About
  • Team
  • Portfolio
  • News
  • Contact
May 7, 2019 in Uncategorized by Christophe Guichard 0 Comments

GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results

Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further de ...

May 7, 2019 in Uncategorized by Christophe Guichard 0 Comments

GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results

Study meets objective of demonstrating safety and pharmacodynamic response Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events Opens way for further deve ...

May 2, 2019 in Uncategorized by Christophe Guichard 0 Comments

Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients

Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial • 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibr ...

Eclosion

Campus Biotech
Innovation Park
Bâtiment F2
Av. Sécheron 15
1201 Geneva
Suisse

Tel: +41 (0)22 544 29 34

    Logo
    Eclosion Ventures © 2021 | Crédits